Important: this page is educational. Dutasteride is a prescription drug and is FDA approved for benign prostatic hyperplasia; use for hair loss is off-label in the United States.
What is dutasteride?
Dutasteride is a 5-alpha reductase inhibitor sold as Avodart. It is FDA approved for benign prostatic hyperplasia and is widely used off-label for male pattern hair loss. It is FDA approved for hair loss in South Korea and Japan, where it has been used at scale for over a decade.
How does dutasteride work?
Two isoforms of 5-alpha reductase convert testosterone to DHT. Finasteride blocks only type 2 and reduces serum DHT by roughly 65 to 70 percent. Dutasteride blocks both type 1 and type 2 and reduces serum DHT by approximately 90 percent. The broader DHT suppression is the reason for its greater effect on follicle preservation and regrowth.
For the full comparison, read finasteride vs dutasteride vs minoxidil.
How is dutasteride dosed?
Standard oral dosing is 0.5 mg daily. Some protocols use 0.5 mg twice or three times per week, which still produces substantial DHT suppression because of the long half-life. Topical and intradermal mesotherapy formulations are compounded; topical reduces systemic exposure while still suppressing scalp DHT.
How long until dutasteride works?
Visible thickening typically appears between months three and six. Peak effect on regrowth occurs between months nine and eighteen, slightly later than finasteride because of the longer time to steady state. Stopping the drug returns DHT to baseline, though the long half-life means washout takes weeks rather than days.
Trial data
In a head-to-head trial of 917 men, dutasteride 0.5 mg produced greater hair count gains than finasteride 1 mg at 24 weeks (Olsen et al., 2006). Subsequent meta-analyses have generally confirmed the magnitude of difference. The side-effect rates between the two are broadly similar in trials, with sexual side effects in the low single digits.
Side effects of dutasteride
Sexual side effects (reduced libido, erectile changes, reduced ejaculatory volume) are reported at rates similar to finasteride. Gynecomastia is reported slightly more often. The long half-life means side effects, if they occur, can persist for weeks after discontinuation as the drug clears.
Mood changes have been reported and deserve attention. As with finasteride, a small minority report persistent symptoms after stopping the drug; the epidemiology is debated.
Who should not take dutasteride?
Contraindicated in pregnancy (relevant to partners) and known hypersensitivity. Use caution with active fertility plans, mood disorders, or elevated baseline PSA. Like finasteride, dutasteride lowers PSA by approximately 50 percent and that adjustment must be applied to screening interpretation.
Mesotherapy and topical dutasteride
Intradermal injection of dilute dutasteride (mesotherapy) and topical 0.01 to 0.1 percent solutions are used to reduce systemic exposure while delivering drug to the scalp. Trial data for these routes is smaller than oral, but early evidence suggests meaningful effect with lower systemic DHT suppression.
Dutasteride vs finasteride
Dutasteride produces more DHT suppression and more hair count gain in trials. Finasteride has more long-term safety data and a shorter washout if side effects arise. Most clinicians start with finasteride and escalate to dutasteride when response is inadequate, or use dutasteride first when the patient prioritizes maximum response.